User:Mr. Ibrahem/Spesolimab

Spesolimab, sold under the brand name Spevigo, is a medication used to treat a flair of generalized pustular psoriasis (GPP). It is given by gradual injection into a vein.

Common side effects include tiredness, nausea, headache, itchiness, bruising at the site of administration, and urinary tract infection. Other side effects may include infection, allergic reactions, and infusion reactions. It is a monoclonal antibody that blocks interleukin-36 receptor (IL1RL2/IL1RAP).

Spesolimab was approved for medical use in the United States in 2022. It is recommended for approval in Europe but is not in the approval process in the United Kingdom as of 2022. In the United States it costs about 54,000 USD per dose as of 2022.